Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is approximately 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the first quarter of 2021.
The analysts price targets range from a high of hundred one dolars to a low of $61.
In the newest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise.
The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products as well as related services, which includes medical, pharmacy, dental, behavioural health, medical relief abilities. The Corporate segment involves in offering management as well as administrative services. The company was developed by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.